Mannkind partners with nrx pharmaceuticals to explore a dry powder formulation of zyesami™ (aviptadil) based on the technosphere® platform

Westlake village, calif., aug. 4, 2021 /prnewswire/ -- mannkind corporation (nasdaq: mnkd) has partnered with nrx pharmaceuticals (nasdaq: nrxp) (nrx) to evaluate the feasibility of formulating a dry powder formulation of zyesami™ (aviptadil), a synthetic form of human vasoactive intestinal peptide (vip) – an endogenous substance produced by the body that helps protect cells against inflammatory conditions.
NRXP Ratings Summary
NRXP Quant Ranking